Stay updated on Pembrolizumab & Cetuximab in HNSCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Cetuximab in HNSCC Clinical Trial page.

Latest updates to the Pembrolizumab & Cetuximab in HNSCC Clinical Trial page
- CheckyesterdayChange DetectedAdded new sections and guidance (No longer looking for participants; How to Read a Study Record; Common Questions; How to Join a Study) and a page revision label (Revision: v3.6.0). Removed the older 'Intervention / Treatment' header and the previous Revision: v3.5.5.SummaryDifference0.4%

- Check8 days agoChange DetectedThe revision label on the page changed from v3.5.4 to v3.5.5. This reflects a metadata update indicating a new version of the page rather than a content change.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedRevision updated from v3.5.3 to v3.5.4 on the page, indicating a minor version update. The content and study details remain unchanged.SummaryDifference0.0%

- Check51 days agoChange DetectedThe page’s displayed site/version label has been updated from “Revision: v3.5.2” to “Revision: v3.5.3,” reflecting a minor maintenance or deployment change with no change to the underlying study information.SummaryDifference0.0%

- Check58 days agoChange DetectedRevision tag updated to v3.5.2.SummaryDifference0.0%

- Check72 days agoChange DetectedThe study’s Conditions list now includes squamous cell carcinoma of the head and neck and nasal cavity/paranasal sinus carcinoma.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab & Cetuximab in HNSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Cetuximab in HNSCC Clinical Trial page.